Nutra Pharma Corp (NPHC)

[maverick81]

Nutra Pharma Files Provisional Patent for the Treatment ALS

PRESS RELEASE:
https://globenewswire.com/news-release/2018/04/10/1467763/0/en/Nutra-Pharma-Files-Provisional-Patent-for-the-Treatment-of-Amyotrophic-Lateral-Sclerosis-ALS.html

"Our primary drug for the treatment of Multiple Sclerosis is RPI-78M,” stated Rik J Deitsch, Chief Executive Officer of Nutra Pharma. “This drug had been used in previous trials for the treatment of ALS with varying results. We now believe that we have discovered the modifications that are necessary to allow RPI-78M to work effectively against ALS progression,” he continued. “We are filing new intellectual property surrounding these findings and will be working with experts in the field to create the new version of the drug. Once the drug is validated, we will move into animal models in ALS that will allow us to pursue broader trials and seek partners to further this research,” he concluded



NPHC IS ON THE LIST WITH BIG PHARMA COMPANIES

Here is the article:
https://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=262292

The global amyotrophic lateral sclerosis treatment market was valued at US$ 51.04 Million in 2016, and is expected to reach US$ 306.6 Million by 2025, expanding at a CAGR of 21.1% from 2017 to 2025.

ALS is a is a rare disorder that affects approximately 30,000 people in the United States, approximately 5,000 new cases are diagnosed each year in the United States. Currently, there is no cure for ALS however, treatments are available to control symptoms and to prevent complications. The U.S. Food and Drug Administration (FDA) has approved only two drugs for the treatment of ALS it includes Riluzole and Edaravone, other medications are prescribe to control ALS symptoms.

It is studied that in the base year 2016, Riluzole (Rilutek) was major revenue generating segment because riluzole was the only approved drug for a treatment of ALS, however patent expiry of Rilutek in 2013 has been negatively impacting the ALS treatment market growth. On the other hand, recently approved medication Edaravone (Radicava) expected to show highest growth rate during forecast period due to its applicability and higher cost would drive market growth. Moreover strong pipeline molecule such as AB-1010 (masitinib), Methycobal (mecobalamin), Arimoclomol, CK-2017357 (CK-357, tirasemtiv) would assist ALS treatment market growth during forecast period.

Key Market Movements:

Factors such as increasing treatment awareness, increase in incidence of ALS, strong pipeline molecules, rising geriatric population, favorable reimbursement policies in some countries and expected launch of newer medication would drive the growth of ALS treatment market globally.
Due to the higher number of unmet needs, manufacturers in the market are focusing on innovation and technological advances in treatment options would further influence the growth of ALS treatment market globally.

Company Profiles:

AB Science
Avicena Group
Biogen
BrainStorm Therapeutics
Covis Pharmaceutical Inc.
Cytokinetics Inc.
Eisai Co. Ltd.
GlaxoSmithKline plc.
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corp.
Neuralstem Inc.
Neuraltus Pharmaceuticals Inc.
Newron Pharmaceuticals S.p.A.
Nutra Pharma Corp.
Pharnext SAS
Q-Therapeutics Inc.


NPHC is on the list with some MAJOR players here, take a look at some of their market caps!! NONE of them anywhere near 5 million MC.

NPHC will have its day and won't be held down here much longer.


Mav